Level-guided anti-thymocyte globulin dosing improved graft-versus-host-free survival; cenobamate raises or lowers brivaracetam depending on dose

The edition in brief

In a randomised phase 3 trial of 204 patients having haploidentical stem cell transplantation, anti-thymocyte globulin dosed to a monitored exposure target gave higher one-year graft-versus-host-disease-free and relapse-free survival than a fixed 10 mg/kg dose (66.7% vs 50.0%; HR 0.666, 95% CI 0.4456 to 0.9954), with less moderate to severe chronic graft-versus-host disease (9.8% vs 22.5%) and fewer grade 3 to 5 infections (44.1% vs 70.6%). A retrospective study of 891 samples from 213 patients found cenobamate had a biphasic effect on brivaracetam concentrations: about 32% higher at 12.5 to 50 mg a day and about 21% lower at 250 to 450 mg a day. An unsupervised machine-learning analysis of 40,127 fluoroquinolone reports in FAERS found a multi-system adverse-event cluster in 10.1% of reports; the authors say this is strictly hypothesis-generating. DORAL, a phase 2 trial in 114 virologically suppressed adults, found one virological failure with a once-daily doravirine plus raltegravir switch. A regulatory entry notes an FDA supplement to a generic exenatide application. A pearl on CYP3A4 inhibitors with opioids closes the edition.